Lutetium-177 Approval And Actinium Production Will Expand Radioisotope Markets

Published
10 Feb 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
€21.67
17.4% undervalued intrinsic discount
14 Aug
€17.90
Loading
1Y
24.1%
7D
-3.0%

Author's Valuation

€21.7

17.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 66%

Shared on23 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget has increased revenue growth from 7.8% to 9.1% and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 9.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.80%

Shared on26 Mar 25
Fair value Increased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Decreased 3.90%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.